Outgoings should be reduced in the March quarter. This payer program is new and appears to be recurring. Take a hit in the initial development with improved margins over time.
• 2Q FY22 cashflow was impacted by two timing issues:
o As part of the new payer program, the Company received all revenue, and paid all product costs within the quarter, whereas typically, programs usually have product costs paid the following quarter resulting in the timing of payments being brought forward from Q3 FY22 to Q2 FY22. No further payments are required to be made for this program.
Add to My Watchlist
What is My Watchlist?
